No 03 2021

The company has been awarded funding through the program “Kompetensförstärkning i småföretag 2026.” The funding will support a new project focused on the development planning of a green, dual-use nebulization technology designed for delivery of MucoLife’s lead therapeutic candidate, MLT-001. MLT-001 is a first-in-class inhaled therapy being developed to rapidly dissolve pathological mucus plugs in […]

The company has received a patent in the United States for its mucoadhesive patch technology, M045A, developed for the treatment of recurrent aphthous stomatitis (mouth ulcers).

Hansa Biopharma and SERB S.A. have announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.

The company's PPD Clinical Research Business is opening a new bioanalytical and biomarker laboratory within GoCo Health Innovation City.

The Series B funding will be used to power the company's AI drug design engine, scale its business globally and progress its drug candidate pipeline.

It has been approved as the first and only aldosterone synthase inhibitor treatment for adults with hypertension.

The company is part of a new EU‑funded consortium developing an AI‑ and robotics‑driven manufacturing platform to secure access to critical medicines during shortages and supply chain disruptions.